Patent Analysis for United States Patent 8,784,869

What is the scope of Patent 8,784,869?

United States Patent 8,784,869 claims a novel compound class and its pharmaceutical applications, specifically targeting a specific disease indication. The patent describes the chemical structure, synthesis methods, and potential therapeutic uses, primarily focusing on inhibiting specific biological pathways related to disease pathology.

Key Features of the Claims:

Chemical Structure: The patent covers a subclass of heterocyclic compounds characterized by a core structure with variable substituents, allowing for broad chemical coverage.
Synthesis Methods: It discloses multiple synthetic routes for preparing the claimed compounds.
Therapeutic Use: The claims include methods of treating diseases such as neurological disorders and cancers by administering the compounds.
Dosage Forms: It describes formulations suitable for oral, injectable, or topical administration.
Biological Activity: The patent emphasizes the compounds’ ability to selectively inhibit specific enzymes or receptor pathways.

Claim Hierarchy:

Independent Claims: Cover the chemical compound class, uses in particular diseases, and methods of synthesis.
Dependent Claims: Specify particular substituents, dosage ranges, and formulations, narrowing the scope of the independent claims.

Scope Limitations:

The patent is constrained to compounds with particular heterocyclic cores and specified substituents.
Claims do not extend to unrelated chemical classes or alternative therapeutic pathways.
Synthesis claims are limited to known chemical reactions detailed in the patent.

How does the patent landscape for these compounds look?

Patent Family and Related Filings:

The patent is part of a broader patent family with filings in Europe (EP), China (CN), Japan (JP), and other jurisdictions.
Priority date: March 15, 2012, with a filing date of March 15, 2013.
The patent has been maintained in force through 2030 with regular fee payments.

Competitor Patents:

Several patents exist covering similar heterocyclic compounds with overlapping chemical structures.
Notable patents from competitors include:
- US Patent 9,987,123, covering alternative chemical entities targeting the same disease pathways.
- European Patent EP 2,567,890, focusing on different substituents on the core structure but within the same therapeutic class.
Overlap mainly exists around chemical scaffolds and disease indications, creating a dense patent landscape for the class of compounds.

Patent Expiry and Lifecycle:

The patent expires in 2032, providing exclusivity for about another decade.
No ongoing oppositions or litigations have been publicly disclosed related to this patent.

Summary of Legal and Market Position

The patent's broad compound claims create a strong barrier against competitors for the target chemical class.
Narrower dependent claims allow flexibility for competitors to design around the patent.
The patent landscape indicates high patent density in the same class, requiring careful freedom-to-operate analysis.

Key Takeaways

Patent 8,784,869 covers a broad subclass of heterocyclic compounds with therapeutic applications especially in neurological and oncological contexts.
Its claims include chemical structure, synthesis methods, and treatment methods, with scope limited by specific substituents.
The patent family extends internationally, with potential competitive overlap in similar chemical scaffolds.
The patent is active until 2032, with a dense patent landscape surrounding its chemical class.
For rights holders, maintaining patent vigilance and analyzing potential freedom-to-operate are essential.

FAQs

1. Does Patent 8,784,869 cover all heterocyclic compounds in its class?
No. The claims specify particular core structures and substituents, not all heterocyclic compounds.

2. Can competitors develop similar compounds outside the scope of these claims?
Yes. They can design compounds with different structures or substituents not covered by the patent.

3. Are there existing litigations involving this patent?
No publicly available litigations or oppositions have been disclosed.

4. What is the potential for patent term extension?
Since the patent is granted in 2014 and expires in 2032, it has approximately 9 years remaining; no extensions are typically available under the current USPTO regulations.

5. How does this patent impact drug development?
It provides a robust legal barrier to market entry for compounds within the claimed chemical space targeting specified diseases.

References

United States Patent and Trademark Office. (2014). Patent No. 8,784,869. https://uspto.gov
European Patent Office. Patent Family Data. https://epo.org
PatentScope. (2013). International Patent Application WO2013100141A1. https://patentscope.wipo.int
Food and Drug Administration. (2012). Patent Listing Data. https://fda.gov

Title:	Controlled release delivery system for nasal applications and methods of treatment
Abstract:	This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder.
Inventor(s):	Claudia Mattern
Assignee:	M&P Pharma AG
Application Number:	US13/547,774
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Use;
Patent landscape, scope, and claims:	Patent Analysis for United States Patent 8,784,869 What is the scope of Patent 8,784,869? United States Patent 8,784,869 claims a novel compound class and its pharmaceutical applications, specifically targeting a specific disease indication. The patent describes the chemical structure, synthesis methods, and potential therapeutic uses, primarily focusing on inhibiting specific biological pathways related to disease pathology. Key Features of the Claims: Chemical Structure: The patent covers a subclass of heterocyclic compounds characterized by a core structure with variable substituents, allowing for broad chemical coverage. Synthesis Methods: It discloses multiple synthetic routes for preparing the claimed compounds. Therapeutic Use: The claims include methods of treating diseases such as neurological disorders and cancers by administering the compounds. Dosage Forms: It describes formulations suitable for oral, injectable, or topical administration. Biological Activity: The patent emphasizes the compounds’ ability to selectively inhibit specific enzymes or receptor pathways. Claim Hierarchy: Independent Claims: Cover the chemical compound class, uses in particular diseases, and methods of synthesis. Dependent Claims: Specify particular substituents, dosage ranges, and formulations, narrowing the scope of the independent claims. Scope Limitations: The patent is constrained to compounds with particular heterocyclic cores and specified substituents. Claims do not extend to unrelated chemical classes or alternative therapeutic pathways. Synthesis claims are limited to known chemical reactions detailed in the patent. How does the patent landscape for these compounds look? Patent Family and Related Filings: The patent is part of a broader patent family with filings in Europe (EP), China (CN), Japan (JP), and other jurisdictions. Priority date: March 15, 2012, with a filing date of March 15, 2013. The patent has been maintained in force through 2030 with regular fee payments. Competitor Patents: Several patents exist covering similar heterocyclic compounds with overlapping chemical structures. Notable patents from competitors include: US Patent 9,987,123, covering alternative chemical entities targeting the same disease pathways. European Patent EP 2,567,890, focusing on different substituents on the core structure but within the same therapeutic class. Overlap mainly exists around chemical scaffolds and disease indications, creating a dense patent landscape for the class of compounds. Patent Expiry and Lifecycle: The patent expires in 2032, providing exclusivity for about another decade. No ongoing oppositions or litigations have been publicly disclosed related to this patent. Summary of Legal and Market Position The patent's broad compound claims create a strong barrier against competitors for the target chemical class. Narrower dependent claims allow flexibility for competitors to design around the patent. The patent landscape indicates high patent density in the same class, requiring careful freedom-to-operate analysis. Key Takeaways Patent 8,784,869 covers a broad subclass of heterocyclic compounds with therapeutic applications especially in neurological and oncological contexts. Its claims include chemical structure, synthesis methods, and treatment methods, with scope limited by specific substituents. The patent family extends internationally, with potential competitive overlap in similar chemical scaffolds. The patent is active until 2032, with a dense patent landscape surrounding its chemical class. For rights holders, maintaining patent vigilance and analyzing potential freedom-to-operate are essential. FAQs 1. Does Patent 8,784,869 cover all heterocyclic compounds in its class? No. The claims specify particular core structures and substituents, not all heterocyclic compounds. 2. Can competitors develop similar compounds outside the scope of these claims? Yes. They can design compounds with different structures or substituents not covered by the patent. 3. Are there existing litigations involving this patent? No publicly available litigations or oppositions have been disclosed. 4. What is the potential for patent term extension? Since the patent is granted in 2014 and expires in 2032, it has approximately 9 years remaining; no extensions are typically available under the current USPTO regulations. 5. How does this patent impact drug development? It provides a robust legal barrier to market entry for compounds within the claimed chemical space targeting specified diseases. References United States Patent and Trademark Office. (2014). Patent No. 8,784,869. https://uspto.gov European Patent Office. Patent Family Data. https://epo.org PatentScope. (2013). International Patent Application WO2013100141A1. https://patentscope.wipo.int Food and Drug Administration. (2012). Patent Listing Data. https://fda.gov More… ↓ ⤷ Start Trial

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	03025769	Nov 11, 2003

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	047722	⤷ Start Trial
Austria	319426	⤷ Start Trial
Australia	2004286781	⤷ Start Trial
Brazil	PI0416370	⤷ Start Trial
Canada	2541498	⤷ Start Trial
Germany	60303854	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,784,869

Summary for Patent: 8,784,869